SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Merck -- Ignore unavailable to you. Want to Upgrade?


To: EepOpp who wrote (618)3/11/1998 8:02:00 AM
From: George Dawson  Read Replies (2) | Respond to of 1580
 
Two favorable New England Journal of Medicine articles on Prilosec:

Yeomans ND, et al. A comparison of omeprazole with ranitidine for ulcers associated with nonsteroidal antiinflammatory drugs. N Engl J Med 1998; 338:719-26.

Omeprazole was superior to zantac (ranitidine) for both healing and prevention - 79% vs. 63% and 72% vs. 59% respectively.

Hawkey CJ, et al. Omeprazole campared with misoprostol for ulcers associated with nonsteroidal antiinflammatory drugs. N Engl J Med 1998; 338: 727-34.

Acute treatment produced similar results for healing 76% (omeprazole) vs. 71% (misoprostol), but omeprazole was superior during maintenace therapy (61 vs 48%) and produced fewer adverse events (59 vs. 48%).

George D.